RxMargin analyses your dispensing income line by line, across reimbursement, rebates, price concessions and procurement, and shows you which lines lose money and how to recover it.
Reimbursement, Drug Tariff changes, Category M, monthly price concessions, supplier rebates and procurement decisions all move independently. A line that made money last quarter can turn into a loss. Most practices simply don't have the time, or the tooling, to track it at the level where the money actually moves.
Illustrative of the approach. Findings and figures are specific to each practice's own data.
Net cost versus reimbursement for every line, so loss-making and over-tariff items surface immediately instead of hiding in the average.
Tracks supplier rebate schemes and monthly price concessions, flagging where you're below the rates you could be earning.
Identifies genuine shortage losses, concession-dependent risk and cheaper same-month sourcing you missed, with the value at stake.
Partner-ready reports, an interactive dashboard, and submission-ready workbooks, delivered through your own secure portal.
A fictional practice, fully built out, an interactive drug-level dashboard, a three-page partner-report PDF, and the prioritised recoverable-margin list. Exactly the format you'd receive, with invented numbers.
Dispensing data, wholesaler invoices and remittances, sent securely. We provide a simple checklist.
Our audited workflow reconciles every line and audits the figures before anything is reported.
Dashboards and reports appear in your private portal, only your practice and our team can see them.
A prioritised list of recoverable margin, refreshed each period so you can track the impact.
See the full method, the line-level maths and the engine behind it → · Or read the latest Tariff Watch →
We treat your data the way a practice has to. Hosting is in the UK, every practice is isolated, and access is by individual sign-in, there's no shared login and no open link.
Each practice can only reach its own material. One practice physically cannot fetch another's files, access is blocked before the request is served.
Each named user signs in with a one-time code to their own email. No shared passwords for you to manage, and access can be removed in seconds.
Content is served from the UK behind an access-controlled front door, so practice material never sits on an open address.
The analysis uses practice-level dispensing, tariff and invoice data, largely aggregate figures, not patient-identifiable records, which keeps the governance burden proportionate.
We align to the NHS Data Security and Protection Toolkit and sign a data-processing agreement with your practice. You remain the data controller; we are your processor, with a defined retention and deletion policy.
Every reimbursement, cost and margin figure is computed by rule against the Drug Tariff, not guessed. Pattern-finding is assisted by AI, but no patient-identifiable data is ever sent to any AI model, and a human signs off every material number.
We provide a data-processing agreement, our DSPT position and our retention and deletion policy before any real practice data is shared.
RxMargin is built and run by practising NHS GP partners who dispense. The method was developed against real dispensing data from a working practice, encodes how a dispensary actually trades, and every material figure is audited by a dispensing GP before it reaches your portal, not generated and left unchecked.
A short, dated read on the Drug Tariff, contract and QOF changes that move dispensing income, and for our practices, a one-page weekly update each time the price concessions change, showing only the lines you dispense. Read the full Tariff Watch →
Email us about an initial review and we'll explain what we'd need and what you'd get back. The first look is no-obligation: we'll tell you, from a single period of data, whether there's enough recoverable margin to be worth your while before you commit to anything.